Among varieties of vasoactive drugs, cilostazol, a selective inhibitor of type 3 phosphodiesterase (PDE), is likely to be a promising agent for AD and CAA (Figure 3). This evidence concerns the gene ALDH7A1 and Alzheimer disease.